Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition
Universidade de Santiago de Compostela · Center for Research in Molecular Medicine and Chronic Diseases · +77 more institutions
Abstract
About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer subtypes within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant…
Citation impact
- FWCI
- 66.36
- Percentile
- 100%
- References
- 62
Authors
1448- BRBernardo Rodríguez–Martín
Universidade de Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases, Universidade de Vigo
- EGEva G. Alvarez
Universidade de Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases, Universidade de Vigo
- ABAdrian Baez‐Ortega
University of Cambridge
- JZJorge Zamora
Universidade de Santiago de Compostela, Wellcome Sanger Institute, Center for Research in Molecular Medicine and Chronic Diseases, Universidade de Vigo
- FSFran Supek
Institució Catalana de Recerca i Estudis Avançats, Institute for Research in Biomedicine
Topics & keywords
- Biology
- Retrotransposon
- Genome
- Genetics
- Computational biology
- Line (geometry)
- Evolutionary biology
- Gene
- Good health and well-being
Funding
- AHAmerican Heart AssociationAward: 17IF33890015
- LKLi Ka Shing Foundation
- SOSundhed og Sygdom, Det Frie Forskningsråd
- WTWellcome TrustAward: FC001202
- FCFrancis Crick InstituteAward: FC001202
- CDCentres de Recerca de CatalunyaAward: ED481A-2018/199
- CRCancer Research UKAward: FC001202
- NINational Institute for Health and Care Research
- ECEuropean CommissionAwards: 703594, 757700, 716290
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAward: P2ELP3_155365
- FWFonds Wetenschappelijk Onderzoek
- KHKorea Health Industry Development InstituteAward: HI16C2387
- AIAssociazione Italiana per la Ricerca sul CancroAward: 17658
- MDMinisterio de Asuntos Económicos y Transformación Digital, Gobierno de España
- XDXunta de GaliciaAwards: ED481A, ED481A-2016/151, ED481A-2017/306, ED431F, ED481A-2018/199
- VRVlaamse regering
- AIAssociazione Italiana Contro le Leucemie-Linfomi e Mieloma
- SISocietà Italiana di Ematologia Sperimentale
- NINational Institutes of HealthAwards: U24CA210978, R01GM124531, 1R01GM099875, P50GM107632, CA172652, R01CA163705, HG007497, NIH R01, R01CA188228
- IEImperial Experimental Cancer Medicine Centre
- MRMedical Research CouncilAward: FC001202
- AEAgencia Estatal de Investigación
- NINational Institute of General Medical SciencesAwards: R01GM124531, P50GM107632